Immunocore (NASDAQ:IMCR) Downgraded by Zacks Research to “Hold”

Posted by on Sep 5th, 2026

Immunocore (NASDAQ:IMCR – Get Free Report) was downgraded by research analysts at Zacks Research from a “strong-buy” rating to a “hold” rating in a research report issued on Thursday, Zacks reports.

Several other research firms have also commented on IMCR. Weiss Ratings reiterated a “sell (e+)” rating on shares of Immunocore in a report on Friday, July 17th. TD Cowen upgraded shares of Immunocore to a “strong-buy” rating in a research report on Monday, August 24th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Immunocore in a research note on Monday, July 13th. Mizuho boosted their target price on shares of Immunocore from $34.00 to $35.00 and gave the company a “neutral” rating in a report on Monday, August 3rd. Finally, Wall Street Zen cut shares of Immunocore from a “buy” rating to a “hold” rating in a research note on Tuesday, July 28th. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $56.38.

View Our Latest Report on Immunocore

Immunocore Trading Down 3.8%

IMCR opened at $36.13 on Thursday. The company has a debt-to-equity ratio of 0.94, a current ratio of 4.47 and a quick ratio of 4.44. The company’s 50 day simple moving average is $34.49 and its two-hundred day simple moving average is $31.75. Immunocore has a 1-year low of $27.56 and a 1-year high of $40.71. The firm has a market capitalization of $1.86 billion, a price-to-earnings ratio of -97.65 and a beta of 0.74.

Immunocore (NASDAQ:IMCR – Get Free Report) last issued its earnings results on Friday, August 7th. The company reported ($0.02) earnings per share for the quarter, missing the consensus estimate of ($0.01) by ($0.01). Immunocore had a negative return on equity of 4.54% and a negative net margin of 4.20%. Analysts expect that Immunocore will post 0.06 EPS for the current fiscal year.

Institutional Trading of Immunocore

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Leonteq Securities AG acquired a new position in Immunocore during the fourth quarter worth $30,000. Harbour Investments Inc. grew its stake in shares of Immunocore by 60.2% in the fourth quarter. Harbour Investments Inc. now owns 1,033 shares of the company’s stock valued at $36,000 after buying an additional 388 shares in the last quarter. Rockefeller Capital Management L.P. purchased a new stake in shares of Immunocore in the 4th quarter valued at $47,000. Arax Advisory Partners raised its holdings in shares of Immunocore by 302.9% in the 4th quarter. Arax Advisory Partners now owns 1,386 shares of the company’s stock valued at $48,000 after buying an additional 1,042 shares during the period. Finally, GAMMA Investing LLC lifted its stake in Immunocore by 202.8% during the 2nd quarter. GAMMA Investing LLC now owns 1,920 shares of the company’s stock worth $61,000 after acquiring an additional 1,286 shares in the last quarter. Hedge funds and other institutional investors own 84.50% of the company’s stock.

Immunocore Company Profile

(Get Free Report)

Immunocore plc is a clinical‐stage biotechnology company focused on the development of novel immunotherapies that harness the body’s own T‐cell response to treat cancer and infectious diseases. The company’s proprietary ImmTAC (immune mobilising monoclonal T‐cell receptors against cancer) platform utilizes engineered, soluble T‐cell receptor (TCR) molecules designed to recognise intracellular peptide–HLA complexes. By redirecting and activating T cells against disease‐associated targets, Immunocore aims to address malignancies and persistent viral infections with high unmet medical need.

The company’s most advanced candidate, tebentafusp, is a bispecific ImmTAC molecule that targets gp100, a melanoma‐associated antigen, and has received regulatory approval for the treatment of metastatic uveal melanoma.

See Also

Analyst Recommendations for Immunocore (NASDAQ:IMCR)

Receive News & Ratings for Immunocore Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunocore and related companies with MarketBeat.com's FREE daily email newsletter.